Related Experiment Video
Updated: Aug 20, 2026

In Vivo Imaging Systems (IVIS) Detection of a Neuro-Invasive Encephalitic Virus
Published on: December 2, 2012
IDN-6556 Idun Pharmaceuticals Inc
1Cedars-Sinai Medical Center, Liver Transplant Dept, 8635 W Third Street, Suite 590W, Los Angeles, CA 90048, USA. Fred.Poordad@cshs.org
Abstract:
IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Equivalents
Modified-Release Drug Delivery Systems: Rate-Programmed II
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Clinically Relevant Drug Product Specifications: Methods of Establishment

